Navigation Links
Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
Date:11/9/2011

statistically significant increase in BMD compared to baseline, consistent with previously reported data.  The placebo arm showed a non-significant decline in BMD.  Safety, tolerability, pharmacokinetics (PK) and biochemical markers of bone formation and resorption were also evaluated in the study.  Positive trends in bone formation at week 24 were seen in both the oral PTH and Forsteo® arms.  Importantly, the 5mg dose of oral PTH demonstrated consistency of exposure at weeks 1 and 24 with the appropriate pulsatile PK profile.  There were no drug-related serious adverse events and no occurrences of hypercalcemia which is a common side effect of PTH therapies.  The most common adverse event in the oral PTH arm was abdominal pain.

Nozer Mehta, Ph.D., Vice President, Research and Development, commented, "Unigene's oral delivery technology achieved therapeutically effective blood levels of the experimental PTH analog and also showed acceptable variability to achieve the primary endpoint of the study.  Compared to calcitonin, PTH is a peptide requiring greater consistency and specific drug delivery criteria to accomplish the appropriate pulsatile PK profile in order to be therapeutically effective to increase BMD. This positive Phase 2 clinical study demonstrates that our oral drug delivery platform was able to meet this rigorous pharmacological objective."

Phase 2 Study Design

The Phase 2 study of oral PTH for the treatment of osteoporosis in postmenopausal women was a multicenter, double blind with respect to placebo, randomized, repeat dose placebo controlled study that included an open label comparator arm of the Forsteo® injectable formulation, and a total of 93 postmenopausal osteoporotic women were enrolled. The primary endpoint was an increase in BMD at the lumbar spine in subjects at 24 weeks following once daily treatment with 5mg orally delivered PTH analog compared to baseline. Seconda
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... ®, provider of RapidResponse ®, a cloud-based supply chain ... S&OP ) service, is proud to be a gold sponsor ... at the Hilton San Diego Bayfront, January 30 – 31, ... , Director of Supply Chain at Amgen, as she presents ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in ... big ideas for 2014 in production and sales of ... produce high-quality, low-cost, DRM-free ebooks and to use the ... The first major development will be bookstore sales in ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Benefits of GMO Foods Versus Organic Food featured in Conversations about ... ... MO (PRWEB) August 11, 2008 -- Today, the Conversations about Plant ... produced by other organizations. The first addition -- "What,s for ...
... Aug. 11 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... quarter of 2008 ended June 30 were,$3,027,497 an ... the second,quarter of 2007. Revenues for the first ... the previous year., The significant revenue improvement ...
... Acquisition will bring together two complementary technologies to extend, reach ... ... -, CINCINNATI, Aug. 11 Ethicon Endo-Surgery announced,today that ... a,privately held developer of the advanced bipolar tissue sealing system ...
Cached Biology Technology:Is GMO Food and Organic Food an Either/Or Proposition? 2Is GMO Food and Organic Food an Either/Or Proposition? 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 2Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 5Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 6Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 7Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 8Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 9Ethicon Endo-Surgery to Acquire SurgRx 2Ethicon Endo-Surgery to Acquire SurgRx 3
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
(Date:4/22/2014)... the University of Kentucky has discovered new methods to ... , The research, led by Peixuan Guo, professor and ... UK College of Pharmacy and Markey Cancer Center, is ... Anionic Polymer Material To Build Robust Structures with Defined ... Daniel L. Jasinski. , The article, which will appear ...
(Date:4/22/2014)... thousands of breeding bird surveys sent in by citizen ... 35 years, wildlife researchers report that most of the ... toward higher elevation in response to climate change, but ... most previous studies of potential climate change impacts on ... other have likely underestimated the effects of environmental warming, ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2Wildlife response to climate change is likely underestimated, experts warn 2
... has developed a computer model that makes use of ... movements to explain how the brain draws on both what ... to anticipate what it needs to develop new motor skills. ... the fact that all people show similar “probable” learning patterns ...
... smoking causes cancer, but new research shows that children could ... , Canadian researchers have demonstrated in mice that smoking can ... that could potentially be inherited by offspring. The results of ... Cancer Research, a journal of the American Association for Cancer ...
... While orange cauliflower may seem unappealing to some, it ... the genetic mutation behind the unusual hue. The finding ... potato, rice, sorghum and wheat. , The genetic ... and colleagues -- and described in the December issue ...
Cached Biology News:Math that powers spam filters used to understand how brain learns to move our muscles 2Cigarette smoke alters DNA in sperm, genetic damage could pass to offspring 2Discovery in orange cauliflower may lead to more nutritious crops 2
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
... SIGNETs BCIP/NBT Chromogen system consists ... chromogen in a single component,solution. ... in the presence of alkaline ... with minimal background noise. ,The ...
...
... Kit - NH2 is primarily used for ... and cellular proteins for tracing. NH2-Reactive B-Phycoerythrin, ... group (NHS), and can easily make a ... or other proteins without any activation process. ...
Biology Products: